Vol. 1 No. 2 (2025), Original Article
Vol. 1 No. 2 (2025)

Prevalence of Metabolic-Associated Steatotic Liver Disease in Patients with Type 2 Diabetes with and without HIV: Retrospective Multicenter Study

Original Article
Published 2025-02-22
Hazem Abosheaishaa
Internal Medicine Department, Icahn School of Medicine at Mount Sinai, NYC Health + Hospitals Queens, NY, USA. image/svg+xml
https://orcid.org/0000-0002-5581-8702
Omar Nassar
Williamsville East High School, Buffalo, NY, USA
https://orcid.org/0000-0001-8492-7433
Mostafa Alfishawy
Infectious Diseases Consultants and Academic Researchers of Egypt (IDCARE), Cairo, Egypt.
Anthony Martinez
Clinical Associate Professor, Department of Medicine, Jacobs School of Medicine & Biomedical Sciences, University at Buffalo, NY USA
PDF

Keywords

Metabolic dysfunction-associated steatotic liver disease (MASLD)
HIV
Type 2 Diabetes Mellitus (T2D)
Antiretroviral Therapy (ART)
Metabolic Complications
TriNetX
HIV-related Comorbidities
Epidemiology

Categories

How to Cite

1.
Abosheaishaa H, Nassar O, Alfishawy M, Martinez A. Prevalence of Metabolic-Associated Steatotic Liver Disease in Patients with Type 2 Diabetes with and without HIV: Retrospective Multicenter Study. ASIDE Int Med. 2025;1(2):8-12. doi:10.71079/ASIDE.IM.02202518
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver AMA

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a frequent complication in patients with Type 2 Diabetes (T2D). This study aims to evaluate the impact of HIV status on the prevalence of MASLD in patients with T2D.

Methods: We utilized the TriNetX global federated health research network to perform a comparative analysis of two cohorts: T2D patients with HIV (Cohort 1) and T2D patients without HIV (Cohort 2). Propensity score matching controlled for confounders such as age, gender, Hemoglobin A1c, LDL, HDL, total cholesterol, triglycerides, BMI, and hypertension. The study was exempt from IRB review as it did not involve direct human subjects, per the University at Buffalo Institutional Review Board.

Results: Initial data included 168,428 patients in Cohort 1 and 9,040,558 in Cohort 2. After matching, each cohort consisted of 166,803 patients. MASLD prevalence was 7.1% in HIV-positive T2D patients and 6.7% in HIV-negative T2D patients, with a significant risk difference (RD = 0.004, 95% CI: 0.002 to 0.006, p < 0.0001). The risk ratio (RR) was 1.062 (95% CI: 1.036 to 1.089), and the odds ratio (OR) was 1.067 (95% CI: 1.039 to 1.096).

Conclusion: HIV-positive T2D patients exhibit a slightly higher risk of developing MASLD than their HIV-negative counterparts. These results underscore the need for specialized screening and management of MASLD in patients with T2D, particularly those living with HIV.

PDF

References

1. Tidwell J, Balassiano N, Shaikh A, Nassar M. Emerging therapeutic options for non-alcoholic fatty liver disease: A systematic review. World J Hepatol. 2023: 1001 [PMID: 37701920 https://doi.org/10.4254/wjh.v15.i8.1001]

2. Guaraldi G, Squillace N, Stentarelli C, Orlando G, D'Amico R, Ligabue G, Fiocchi F, Zona S, Loria P, Esposito R, Palella F. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis. 2008: 250 [PMID: 18532884 https://doi.org/10.1086/589294]

3. Maurice JB, Patel A, Scott AJ, Patel K, Thursz M, Lemoine M. Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection. AIDS. 2017: 1621 [PMID: 28398960 https://doi.org/10.1097/QAD.0000000000001504]

4. Manzano-Nunez R, Rivera-Esteban J, Navarro J, Bañares J, Sena E, Schattenberg JM, Lazarus JV, Curran A, Pericàs JM. Uncovering the NAFLD burden in people living with HIV from high- and middle-income nations: a meta-analysis with a data gap from Subsaharan Africa. J Int AIDS Soc. 2023: e26072 [PMID: 36924219 https://doi.org/10.1002/jia2.26072]

5. Bischoff J, Gu W, Schwarze-Zander C, Boesecke C, Wasmuth JC, van Bremen K, Dold L, Rockstroh JK, Trebicka J. Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART). EClinicalMedicine. 2021: 101116 [PMID: 34522873 https://doi.org/10.1016/j.eclinm.2021.101116]

6. Allende DS, Cummings O, Sternberg AL, Behling CA, Carpenter D, Gill RM, Guy CD, Yeh MM, Gawrieh S, Sterling RK, Naggie S, Loomba R, Price JC, McLaughlin M, Hadigan C, Crandall H, Belt P, Wilson L, Chalasani NP, Kleiner DE, Hiv N, Groups NCR. MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls. Aliment Pharmacol Ther. 2024: 1351 [PMID: 39238213 https://doi.org/10.1111/apt.18236]

7. Cinque F, Saeed S, Kablawi D, Ramos Ballesteros L, Elgretli W, Moodie EEM, Price C, Monteith K, Cooper C, Walmsley SL, Pick N, Murray MCM, Cox J, Kronfli N, Costiniuk CT, de Pokomandy A, Routy JP, Lebouche B, Klein MB, Sebastiani G. Role of fatty liver in the epidemic of advanced chronic liver disease among people with HIV: protocol for the Canadian LIVEHIV multicentre prospective cohort. BMJ Open. 2023: e076547 [PMID: 37607785 https://doi.org/10.1136/bmjopen-2023-076547]

8. Wong RJ, Yang Z, Yeoh A, Do A, Ahmed A, Cheung R. Impact of HIV Infection on Liver and Cardiovascular Outcomes in Veterans With Metabolic Dysfunction-Associated Steatotic Liver Disease. Am J Gastroenterol. 2024: 1841 [PMID: 38477465 https://doi.org/10.14309/ajg.0000000000002760]

9. Kalopitas G, Arvanitakis K, Tsachouridou O, Malandris K, Koufakis T, Metallidis S, Germanidis G. Metabolic Dysfunction-Associated Steatotic Liver Disease in People Living with HIV-Limitations on Antiretroviral Therapy Selection. Life (Basel). 2024: [PMID: 38929725 https://doi.org/10.3390/life14060742]

10. Guaraldi G, Milic J, Renzetti S, Motta F, Cinque F, Bischoff J, Desilani A, Conti J, Medioli F, Del Monte M, Kablawi D, Elgretli W, Calza S, Mussini C, Rockstroh JK, Sebastiani G. The effect of weight gain and metabolic dysfunction-associated steatotic liver disease on liver fibrosis progression and regression in people with HIV. AIDS. 2024: 1323 [PMID: 38597416 https://doi.org/10.1097/QAD.0000000000003903]

11. Bialy M, Czarnecki M, Inglot M. Impact of Combination Antiretroviral Treatment on Liver Metabolic Health in HIV-Infected Persons. Viruses. 2023: [PMID: 38140673 https://doi.org/10.3390/v15122432]

12. Moragrega Á, Busca C, Apostolova N, Olveira A, Martín-Carbonero L, Valencia E, Moreno V, Bernardino JI, Abadía M, González-García J, Esplugues J, Montes M, Blas-García A. Rilpivirine Activates STAT1 in Non-Parenchymal Cells to Regulate Liver Injury in People Living with HIV and MASLD. Biomedicines. 2024: https://doi.org/10.3390/biomedicines12071454]

13. Martinez-Sanz J, Talavera-Rodriguez A, Diaz-Alvarez J, Rosas Cancio-Suarez M, Rodriguez JM, Alba C, Montes ML, Martin-Mateos R, Burgos-Santamaria D, Moreno S, Serrano-Villar S, Sanchez-Conde M. A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease. Front Immunol. 2023: 1297378 [PMID: 38162648 https://doi.org/10.3389/fimmu.2023.1297378]

14. Cinque F, Cespiati A, Lombardi R, Guaraldi G, Sebastiani G. Nutritional and Lifestyle Therapy for NAFLD in People with HIV. Nutrients. 2023: [PMID: 37111209 https://doi.org/10.3390/nu15081990]

15. Krahn T, Martel M, Sapir-Pichhadze R, Kronfli N, Falutz J, Guaraldi G, Lebouche B, Klein MB, Wong P, Deschenes M, Ghali P, Sebastiani G. Nonalcoholic Fatty Liver Disease and the Development of Metabolic Comorbid Conditions in Patients With Human Immunodeficiency Virus Infection. J Infect Dis. 2020: 787 [PMID: 32249283 https://doi.org/10.1093/infdis/jiaa170]

16. Gupta PK, Tyagi S, Mathews SE, Saini R, Sesama H, Chugh A, Singh K, Chawla MPS. Non-Alcoholic fatty liver disease and metabolic syndrome in patients with HIV/AIDS and its correlation with antiretroviral therapy and severity of disease. Sri Lanka Journal of Medicine. 2023: 18 https://doi.org/10.4038/sljm.v32i1.348]

17. Abere S, Oyan B. Duration of HAART use: A key prognosticator for NAFLD in HAART experienced HIV patients. GSC Advanced Research and Reviews. 2022: 071 https://doi.org/10.30574/gscarr.2022.10.3.0077]

18. Nassar M, Misra A, Bloomgarden Z. Impact of treatment with GLP-1RAs on suicide attempts in adults persons with type 2 diabetes: A retrospective comparative effectiveness study based on a global TriNetX health research database. J Diabetes. 2024: e13547 [PMID: 38501220 https://doi.org/10.1111/1753-0407.13547]

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2025 ASIDE Internal Medicine

Most read articles by the same author(s)

Similar Articles

You may also start an advanced similarity search for this article.